EN
IT
Non-invasive Prenatal Screening
Technological advancements have determined the introduction of sophisticated genetic tests into medical practice, for the evaluation of the pregnancy and fetal health. GENOMICA can boast one of the most extensive experience in the field of prenatal diagnostics, which allow the company to make the most advanced technologies available in the field to pregnant women and their gynecologists, for the diagnosis of chromosomal abnormalities and genetic disorders in the fetus.
The non-invasive prenatal screening, called NIPT (Non Invasive Prenatal Test), allows screening for fetal chromosomal anomalies during pregnancy. A simple maternal blood sample is sufficient to study circulating free fetal DNA (cff-DNA). Through this genetic test it is possible to detect in the fetus common and rare chromosomal aneuploidies, segmental imbalances (deletions or duplications), mendelian genetic disorders. It is a rapid, safe and reliable screening test that can be carried out starting from the 10th week of gestation, even in the case of twin pregnancies and IVF derived pregnancies. The test result is available within a few working days.
The most advanced non-invasive prenatal test (NIPT) that uses groundbreaking technologies. Through analysis of circulating cell-free fetal DNA (cfDNA) in maternal blood, it screens for genome-wide chromosomal abnormalities (common and rare aneuploidies, segmental imbalances), 50 microdeletion/microduplication syndromes and up to 470+ severe inherited and de novo genetic disorders in the fetus, providing unparalleled accuracy and detection compared to other NIPT.
Brochure Website
PrenatalAdvance Karyo Plus test couples leading technology with unparalleled insight to offer the most advanced noninvasive prenatal test. Unlike any other NIPT available to date, focusing only on detection of common aneuploidies, it screens every chromosome in the fetal genome, providing information previously only available from a fetal karyotype analysis. PrenatalAdvance Karyo Plus can also detect, accross the fetal genome, other chromosomal abnormalities that may go undiagnosed, such as structural chromosomal aberrations (deletions or duplications), rare aneuploidies (e.g. trisomy 9,16, 22) and 50 microdeletions / microduplications syndromes and up to 470+ severe inherited and de novo genetic disorders in the fetus, providing unparalleled accuracy and detection compared to other NIPT.
The most advanced non-invasive prenatal test (NIPT) that uses groundbreaking technologies. Through analysis of circulating cell-free fetal DNA (cfDNA) in maternal blood, it screens for severe genetic disorders in the fetus, allowing a more complete picture of the risk of a pregnancy being affected by a genetic disease.
Brochure Website
A non-invasive blood test that can determine the fetal RhD status through analysis of circulating cell free fetal DNA. The test is performed only for pregnant women Rh(D) negative, with male partner Rh(D) positive
An advanced non-invasive prenatal paternity test that uses groundbreaking technologies. Through analysis of circulating cell-free fetal DNA (cfDNA) in maternal blood, it allows to determine the biological paternity without requiring invasive prenatal diagnosis techniques, such as CVS or amniocentesis.
